Johnson & Johnson's Evanmab Wins New China Approval for NSCLC Treatment

Johnson & Johnson (JNJ.US) has announced that its EGFR/c-MET bispecific antibody, "Evanmab," has been approved for a new indication in China. The approval allows for the use of Evanmab in combination with Lanreotide for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have specific EGFR mutations.

This approval marks a significant milestone for Johnson & Johnson, as it expands the therapeutic options available for patients with NSCLC in China. NSCLC is one of the most common types of lung cancer, and patients with specific EGFR mutations often face limited treatment options. The combination of Evanmab and Lanreotide offers a new approach to targeting both EGFR and c-MET pathways, which are known to play crucial roles in the development and progression of NSCLC.

The approval is based on clinical trial data that demonstrated the efficacy and safety of the combination therapy. The trial results showed that the combination of Evanmab and Lanreotide provided significant clinical benefits to patients, including improved progression-free survival and overall response rates. These findings underscore the potential of bispecific antibodies in cancer treatment, as they can simultaneously target multiple pathways involved in tumor growth and metastasis.

Evanmab was first approved in China in February 2025 for the treatment of NSCLC patients with EGFR exon 20 insertion mutations. In April 2025, it received another approval for use in combination with chemotherapy for patients with EGFR TKI-treated locally advanced or metastatic NSCLC. This latest approval is the third indication for Evanmab in China, further solidifying its role in the treatment of NSCLC.

Globally, Evanmab has been approved for four indications related to NSCLC, highlighting its broad applicability and effectiveness in treating this disease. The drug was first granted accelerated approval in the United States in May 2021, demonstrating its rapid development and recognition in the global oncology community.

The approval of Evanmab for this new indication is expected to have a positive impact on the treatment landscape for NSCLC in China. It provides healthcare professionals with an additional tool to manage this challenging disease, potentially improving patient outcomes and quality of life. The approval also highlights Johnson & Johnson's commitment to innovation in oncology and its efforts to bring new and effective treatments to patients in need.

In summary, the approval of Evanmab for the treatment of specific EGFR-mutated NSCLC in combination with Lanreotide represents a significant advancement in the management of this disease. The combination therapy offers a novel approach to targeting multiple pathways involved in tumor growth, providing patients with a new treatment option that has shown promising clinical benefits. This approval underscores Johnson & Johnson's dedication to developing innovative therapies for cancer patients and its ongoing efforts to improve patient outcomes.